The gastrointestinal cancer condition center is a comprehensive resource for clinical news and expert insights on gastrointestinal cancer. Read more at OncLive.
June 1st 2025
Sara Char, MD, on the association between the empirical dietary inflammatory pattern and survival outcomes in stage III colon cancer.
Neoadjuvant therapy with PAXG chemotherapy prolonged event-free survival vs mFOLFIRINOX in patients with stage I to III pancreatic ductal adenocarcinoma.
Adjuvant nivolumab generated durable DFS and DMFS outcomes in resectable esophageal or GEJ cancer.
TTFields plus chemotherapy improved overall survival in unresectable, locally advanced pancreatic ductal adenocarcinoma.
The addition of durvalumab to perioperative FLOT improved event-free survival in resectable gastric/GEJ adenocarcinoma.
A post hoc analysis of NAPOLI-3 reveals insights on long-term survivors with pancreatic cancer who received NALIRIFOX.
A fruquintinib regimen appeared safe and effective when used as a frontline treatment in esophageal squamous cell carcinoma.
May 31st 2025
Vincent Picozzi, MD, discusses the addition of TFields to gemcitabine and nab-paclitaxel in locally advanced pancreatic ductal adenocarcinoma.
T-DXd demonstrated clinically meaningful antitumor responses as second-line treatment in HER2-positive gastric/GEJ cancer.
May 30th 2025
Here is your snapshot of all therapeutic options that were approved by the FDA in May 2025 spanning tumor types.
China’s NMPA approved zanidatamab for previously treated, unresectable or metastatic, HER2-positive biliary tract cancer.
May 29th 2025
CRISPR-Cas9–mediated CISH gene knockout TIL therapy was well tolerated and demonstrated early signals of efficacy in metastatic GI epithelial cancer.
EBC-129 has been awarded fast track designation from the FDA for patients with pancreatic ductal adenocarcinoma.
May 28th 2025
NEOPAN data support the superiority of FOLFIRINOX over gemcitabine in locally advanced pancreatic carcinoma.
Nataliya Uboha, MD, PhD, underscores the crucial role of molecular profiling for guiding first-line treatment approaches in esophageal adenocarcinoma.
May 26th 2025
Tanios S. Bekaii-Saab, MD, FACP, discusses the use of tislelizumab plus chemotherapy in unresectable or metastatic ESCC.
May 23rd 2025
GI cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.
May 21st 2025
Ahead of the 2025 ASCO Annual Meeting, experts in gastrointestinal cancers provide their top anticipated studies they will be watching for at the meeting.
May 20th 2025
Robert Herman Vonderheide, MD, DPhil, discussed potential immune responses with immunotherapy plus KRAS inhibition in pancreatic cancer models.
May 19th 2025
Yelena Y. Janjigian, MD, discusses the safety of nivolumab plus chemotherapy for the first-line treatment of patients with gastric/GEJ/esophageal cancer.